That's a premium of about 60% to Tourmaline Bio's closing price of about $30 on Monday. Tourmaline Bio stock rose as much as 57$47.25. Novartis fell slightly in early trading. Novartis has been on the hunt for acquisitions that could boost its sales beyond 2025. The company is facing competition from cheap generics later this year for three key drugs, including its top-selling heart medicine Entresto. In April, the comp ...